Randomized trial evaluates efficacy and safety of combination therapy in KRAS-mutated low-grade serous ovarian cancer, suggesting potential for durable disease control.
INTRODUCTION: being the predominant driver in recurrent disease, for which effective and durable treatment options remain limited. AREAS COVERED: This article reviews the mechanistic rationale for combined RAF/MEK and focal adhesion kinase (FAK) inhibition in LGSOC, focusing on avutometinib (a first-in-class RAF/MEK clamp) and defactinib (a selective FAK inhibitor). A structured review of preclinical and clinical evidence was conducted, including key findings from phase I FRAME and phase II RAMP-201 trials. Efficacy outcomes, safety and tolerability profiles, and the current regulatory landscape, including accelerated approval in the United States and ongoing phase III evaluation, are discussed. EXPERT OPINION: -mutant tumors. If confirmed in phase III trials, this combination may establish a molecularly informed disease-specific treatment paradigm with the potential for more durable disease control than existing therapies.
No takes yet. Share an insight, caveat, or question.
Podder et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: